<DOC>
	<DOCNO>NCT01599117</DOCNO>
	<brief_summary>The investigator hypothesize udenafil , newly develop phosphodiesterase type 5 inhibitor , would improve symptom , exercise capacity hemodynamic status patient heart failure preserve ejection fraction ( HFpEF ) .</brief_summary>
	<brief_title>A Randomized Trial Udenafil Therapy Patients With Heart Failure With Preserved Ejection Fraction ULTIMATE-HFpEF</brief_title>
	<detailed_description>Heart failure preserve ejection fraction ( HFpEF ) consider mild form heart failure 1990 's . However , prevalence prognosis HFpEF find similar heart failure reduce ejection fraction ( HFrEF ) widely accept HFpEF separate entity heart failure , substantially different HFrEF . The pathophysiology HFpEF contract increased stiffness impaired relaxation leave ventricle ( LV ) , cause increase LV end-diastolic pressure pulmonary venous pressure . These may lead dyspnea , limited exercise capacity , pulmonary congestion patient . Current guideline treatment HFpEF include appropriate blood pressure control , rate control atrial fibrillation , use diuretic pulmonary peripheral edema . But evidence-based effective treatment strategy HFpEF . Recently , phosphodiesterase type 5 ( PDE-5 ) inhibitor ( eg . sildenafil , vardenafil , tadalafil ) show promising effect heart failure , reduce pulmonary vascular resistance , improve LV systolic diastolic function , exercise capacity quality life . These result infer PDE-5 inhibitor might beneficial patient HFpEF . Udenafil ( Zydena ) , newly develop PDE-5 inhibitor , prove similar efficacy safety profile , compare PDE-5 inhibitor . Also , laboratory data show udenafil inhibits ventricular hypertrophy fibrosis rat heart failure model . Based result , hypothesize udenafil would improve symptom , exercise capacity hemodynamic status patient HFpEF . In 12-week , randomize , double-blind , placebo-controlled trial , patient HFpEF enrol accord eligibility criterion . After randomization , study participant assign receive either 50mg udenafil placebo two time day 4 week , dosage double 100mg two time day next 8 week . Participants attend study visit baseline week 4 12 . Physical examination , medical history review , blood sample collection electrocardiogram conduct study visit . At baseline week 12 , participant undergo cardiopulmonary exercise test exercise echocardiography . At every study visit , researcher collect health information .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>Previous clinical diagnosis heart failure preserve ejection fraction ( diastolic heart failure ) current New York Heart association ( NYHA ) class IIIV symptom Left ventricular ejection fraction ( LVEF ) great equal 50 % , determine echocardiography 12 month study entry Has experience least one follow 12 month study entry 1 . Hospitalization decompensated heart failure 2 . Acute treatment intravenous loop diuretic hemofiltration 3 . E/E ' ratio great equal 15 measure echocardiography 4 . E/E ' ratio great equal 8 , leave atrial volume index ( LAVI ) great equal 40 ml/m2 measure echocardiography 5 . E/E ' ratio great equal 8 measure echocardiography , plasma BNP concentration great equal 200 pg/ml History reduce LVEF ( less 50 % ) Valve disease ( great mild stenosis regurgitation ) Hypertrophic cardiomyopathy Infiltrative inflammatory myocardial disease Pericardial disease Obstructive restrictive lung disease Primary pulmonary arteriopathy Has neuromuscular , orthopedic , noncardiac condition prevents individual exercise testing Has experience myocardial infarction unstable angina , undergone percutaneous coronary intervention ( PCI ) coronary artery bypass grafting ( CABG ) within 60 day study entry Noncardiac illness estimate life expectancy le 1 year time study entry , base judgment physician Current use nitrate therapy Current use phosphodiesterase 5 inhibitor ( ie . sildenafil , vardenafil , tadalafil ) treatment impotence pulmonary artery hypertension Current use cytochrome P450 3A4 inhibitor ( ie . ketoconazole , itraconazole , erythromycin , saquinavir , cimetidine , protease inhibitor HIV ) Severe hypotension ( systolic blood pressure [ SBP ] le 90mmHg diastolic blood pressure [ DBP ] le 50mmHg ) uncontrolled hypertension ( SBP great 180mmHg DBP great 100mmHg ) Resting heart rate ( HR ) great 100bpm Known severe renal dysfunction ( estimate glomerular filtration rate [ GFR ] le 30ml/min/1.73m2 modified modification diet renal disease [ MDRD ] equation ) Known severe liver disease ( alanine transaminase [ ALT ] aspartate aminotransferase [ AST ] level great three time upper normal limit , alkaline phosphatase [ ALP ] total bilirubin great two time upper normal limit ) History leukemia , multiple myeloma penile deformity increase risk priapism ( eg . Peyronie 's disease ) History proliferative diabetic retinopathy , retinitis pigmentosa , nonischemic optic neuropathy , unexplained visual disturbance Female patient currently pregnant woman childbearing age use contraception Listed heart transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Heart Failure Preserved Ejection Fraction</keyword>
	<keyword>Diastolic Heart Failure</keyword>
	<keyword>Exercise Capacity</keyword>
	<keyword>Cardiopulmonary Exercise Test</keyword>
	<keyword>Udenafil ( Zydena )</keyword>
	<keyword>Phosphodiesterase Type 5 Inhibitors</keyword>
</DOC>